{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:49:14Z","timestamp":1789364954503,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T00:00:00Z","timestamp":1427155200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40265-015-0380-3","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T17:40:23Z","timestamp":1427132423000},"page":"769-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia"],"prefix":"10.1007","volume":"75","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,24]]},"reference":[{"key":"380_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4614-7959-8_50","volume-title":"Atlas of lymph node pathology","author":"RN Miranda","year":"2013","unstructured":"Miranda RN, Khoury JD, Medeiros LJ. Mantle cell lymphoma. In: Miranda RN, Khoury JD, Medeiros LJ, editors. Atlas of lymph node pathology. New York: Springer; 2013. p. 229\u201335."},{"issue":"2","key":"380_CR2","first-page":"605","volume":"29","author":"J Boelens","year":"2009","unstructured":"Boelens J, Lust S, Vanhoecke B, et al. Chronic lymphocytic leukemia. Anticancer Res. 2009;29(2):605\u201315.","journal-title":"Anticancer Res."},{"issue":"4","key":"380_CR3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511\u20138.","journal-title":"J Clin Oncol."},{"issue":"4","key":"380_CR4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","volume":"159","author":"P McKay","year":"2012","unstructured":"McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol. 2012;159(4):405\u201326.","journal-title":"Br J Haematol."},{"key":"380_CR5","doi-asserted-by":"crossref","unstructured":"Dreyling M. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. 2014 educational book: American Society of Clinical Oncology; 2014. p. 191\u20138.","DOI":"10.14694\/EdBook_AM.2014.34.191"},{"issue":"11","key":"380_CR6","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","volume":"109","author":"WG Wierda","year":"2007","unstructured":"Wierda WG, O\u2019Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679\u201385.","journal-title":"Blood."},{"issue":"1","key":"380_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-012-0147-9","volume":"8","author":"JR Brown","year":"2013","unstructured":"Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton\u2019s tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013;8(1):1\u20136.","journal-title":"Curr Hematol Malig Rep."},{"issue":"1","key":"380_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11899-012-0143-0","volume":"8","author":"L Sellner","year":"2013","unstructured":"Sellner L, Denzinger S, Dietrich S, et al. What do we do with chronic lymphocytic leukemia with 17p deletion? Curr Hematol Malig Rep. 2013;8(1):81\u201390.","journal-title":"Curr Hematol Malig Rep."},{"issue":"Suppl 6","key":"380_CR9","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","volume":"22","author":"B Eichhorst","year":"2011","unstructured":"Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50\u20134.","journal-title":"Ann Oncol."},{"issue":"2","key":"380_CR10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40265-014-0338-x","volume":"75","author":"JE Arnason","year":"2015","unstructured":"Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015;75(2):143\u201355.","journal-title":"Drugs."},{"key":"380_CR11","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) non-Hodgkin\u2019s lymphomas. 2015. https:\/\/www.nccn.org . Accessed 3 Feb 2015."},{"issue":"Suppl 3","key":"380_CR12","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii83\u201392.","journal-title":"Ann Oncol."},{"issue":"10","key":"380_CR13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1470-2045(14)70388-2","volume":"15","author":"P Ghia","year":"2014","unstructured":"Ghia P. Ibrutinib: better combined with other drugs? Lancet Oncol. 2014;15(10):1043\u20134.","journal-title":"Lancet Oncol."},{"issue":"10","key":"380_CR14","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416\u201323.","journal-title":"J Clin Invest."},{"issue":"3","key":"380_CR15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649\u201357.","journal-title":"Leukemia."},{"issue":"1","key":"380_CR16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","volume":"9","author":"JA Burger","year":"2014","unstructured":"Burger JA. Bruton\u2019s tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9(1):44\u20139.","journal-title":"Curr Hematol Malig Rep."},{"issue":"10","key":"380_CR17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271\u20137.","journal-title":"Leuk Res."},{"issue":"23","key":"380_CR18","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood."},{"issue":"6","key":"380_CR19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175\u201384.","journal-title":"Blood."},{"key":"380_CR20","unstructured":"US FDA. Imbruvica (ibrutinib) capsules: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov . Accessed 12 Mar 2015."},{"key":"380_CR21","unstructured":"European Medicines Agency. Imbruvica (ibrutinib) hard capsules: EU summary of product characteristics. 2014. http:\/\/ec.europa.eu . Accessed 12 Mar 2015."},{"issue":"2","key":"380_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","volume":"74","author":"F Cameron","year":"2014","unstructured":"Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74(2):263\u201371.","journal-title":"Drugs."},{"key":"380_CR23","unstructured":"Johnson and Johnson. Application submitted to the EMA to expand the therapeutic indication for Imbruvica\u00ae (ibrutinib) to include treatment of Waldenstr\u00f6m\u2019s macroglobulinemia. 2014. http:\/\/www.investor.jnj.com . Accessed 9 Feb 2015."},{"issue":"29","key":"380_CR24","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075\u201380.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"21","key":"380_CR25","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SEM Herman","year":"2014","unstructured":"Herman SEM, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286\u201395.","journal-title":"Blood."},{"issue":"14","key":"380_CR26","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MFM, et al. Egress of CD19+ CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412\u201324.","journal-title":"Blood."},{"issue":"1","key":"380_CR27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88\u201394.","journal-title":"J Clin Oncol."},{"issue":"1","key":"380_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med."},{"issue":"11","key":"380_CR29","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/leu.2014.122","volume":"28","author":"SEM Herman","year":"2014","unstructured":"Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28(11):2188\u201396.","journal-title":"Leukemia."},{"issue":"3","key":"380_CR30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med."},{"issue":"6","key":"380_CR31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med."},{"issue":"12","key":"380_CR32","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810\u20137.","journal-title":"Blood."},{"issue":"24","key":"380_CR33","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286\u201394.","journal-title":"N Engl J Med."},{"key":"380_CR34","doi-asserted-by":"crossref","unstructured":"Martin P, Maddocks KJ, Noto K, et al. Poor overall survival of patients with ibrutinib-resistant mantle cell lymphoma [abstract no. 3047]. In: 56th ASH Annual Meeting and Exposition; 2014.","DOI":"10.1182\/blood.V124.21.3047.3047"},{"issue":"9","key":"380_CR35","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3\u00a0K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4(9):1022\u201335.","journal-title":"Cancer Discov."},{"key":"380_CR36","doi-asserted-by":"crossref","unstructured":"Wang M, Rule S, Martin P, et al. Single-agent ibrutinib demonstrates safety and durability of response at 2\u00a0years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study [abstract no. 4453]. Blood. 2014;124(21).","DOI":"10.1182\/blood.V124.21.4453.4453"},{"key":"380_CR37","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Jones JA, Coutre S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE\u2122-17 trial [abstract no. 327]. In: 56th ASH Annual Meeting and Exposition; 2014.","DOI":"10.1182\/blood.V124.21.327.327"},{"key":"380_CR38","doi-asserted-by":"crossref","unstructured":"Brown JR, Hillmen P, O\u2019Brien S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE\u2122 trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma [abstract no. 3331]. Blood. 2014;124(21).","DOI":"10.1182\/blood.V124.21.3331.3331"},{"key":"380_CR39","doi-asserted-by":"crossref","unstructured":"Barrientos JC, O\u2019Brien S, Brown JR, et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE\u2122 study of ibrutinib vs ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma [abstract no. 4696]. In: 56th ASH Annual Meeting and Exposition; 2014.","DOI":"10.1182\/blood.V124.21.4696.4696"},{"issue":"25","key":"380_CR40","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJH, Ooi JYY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829\u201330.","journal-title":"Blood."},{"issue":"10","key":"380_CR41","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood-2015-01-621466","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Hillmen P, James DF. Response: additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. Blood. 2015;125(10):1673.","journal-title":"Blood."},{"issue":"1","key":"380_CR42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125(1):48\u201355.","journal-title":"Blood."},{"issue":"7","key":"380_CR43","doi-asserted-by":"crossref","first-page":"A614","DOI":"10.1016\/j.jval.2014.08.2163","volume":"17","author":"V Tongbram","year":"2014","unstructured":"Tongbram V, Sengupta N, Gaudig M, et al. Comparative effectiveness of treatments for relapsed or refractory mantle cell lymphoma (R\/R MCL), using matching adjusted indirect comparison [abstract no. PCN5]. Value Health. 2014;17(7):A614\u20135.","journal-title":"Value Health."},{"issue":"1","key":"380_CR44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","volume":"100","author":"F Roit Da","year":"2015","unstructured":"Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100(1):77\u201386.","journal-title":"Haematologica."},{"issue":"10","key":"380_CR45","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","volume":"15","author":"JA Burger","year":"2014","unstructured":"Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090\u20139.","journal-title":"Lancet Oncol."},{"key":"380_CR46","doi-asserted-by":"crossref","unstructured":"Wang M, Hagemeister F, Westin JR, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial [abstract no. 627]. In: 56th ASH Annual Meeting and Exposition; 2014.","DOI":"10.1016\/j.clml.2015.07.131"},{"issue":"1","key":"380_CR47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/fon.14.119","volume":"11","author":"M Hallek","year":"2015","unstructured":"Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed\/refractory chronic lymphocytic leukemia. Future Oncol. 2015;11(1):51\u20139.","journal-title":"Future Oncol."},{"issue":"7","key":"380_CR48","doi-asserted-by":"crossref","first-page":"A620","DOI":"10.1016\/j.jval.2014.08.2198","volume":"17","author":"F Pan","year":"2014","unstructured":"Pan F, Peng S, Sorensen S, et al. Simulation model of ibrutinib for chronic lymphocytic leukemia (CLL) with prior treatment [abstract no. PCN40]. Value Health. 2014;17(7):A620\u20131.","journal-title":"Value Health."},{"issue":"7","key":"380_CR49","doi-asserted-by":"crossref","first-page":"A620","DOI":"10.1016\/j.jval.2014.08.2196","volume":"17","author":"S Peng","year":"2014","unstructured":"Peng S, Sorensen S, Pan F, et al. Simulation model of ibrutinib in treatment of relapsed or refractory mantle cell lymphoma (MCL) [abstract no. PCN38]. Value Health. 2014;17(7):A620.","journal-title":"Value Health."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0380-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0380-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0380-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T03:30:34Z","timestamp":1598844634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0380-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,24]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0380-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,24]]}}}